Overview#
Goldman Sachs has recently downgraded Valneva SE's stock rating from Neutral to Sell, citing uncertainties regarding the company's Lyme disease vaccine. The price target for Valneva has also been reduced from EUR 3.25 to EUR 2.15. Currently, the stock is trading at $5.93, reflecting a 33% decline year-to-date and hovering just above its 52-week low of $5.43.
Challenges Faced#
The downgrade comes after Valneva faced several setbacks over the past year, including the withdrawal of its Ixchiq product and disappointing results from the VALOR trial, which aimed to evaluate the effectiveness of its Lyme disease vaccine candidate, PF-07307405. Goldman Sachs has expressed concern over the uncertain pathway to regulatory approval for this vaccine, especially given the company's negative gross profit margin of 10% and significant EBITDA losses of $76 million in the last year.
VALOR Trial Results#
The VALOR trial did show some positive results, indicating a 73.2% efficacy of the vaccine compared to a placebo starting 28 days after the fourth dose. However, the trial did not meet its pre-set statistical requirements due to fewer Lyme disease cases than expected during the study. Goldman Sachs noted that there is no precedent for vaccine approval under such circumstances, which adds to the uncertainty surrounding Valneva's future.
Market Reactions and Future Outlook#
Despite the downgrade, other analysts have differing views on Valneva's potential. Jefferies has maintained a Buy rating with a price target of $15, while Guggenheim has adjusted its target to $11 but also holds a Buy rating. Recent earnings reports showed Valneva exceeding revenue expectations, which may provide some optimism. However, Goldman Sachs remains cautious, indicating limited potential for positive developments in the near future.